Taro licenses Foamix lice product

By AVI KRAWITZ
October 17, 2006 08:24

Foamix will transfer technology to Haifa-based Taro, which will upscale, manufacture, register and commercialize PerFoam 1% for distribution in Israel and the Palestinian territories.




Ness Tsiona-based Foamix, a developer of topical foam delivery systems for dermatology and other applications, said Monday it licensed its new lice treatment product PerFoam 1% to Taro Pharmaceutical Industries. Foamix will transfer technology to Haifa-based Taro, which will upscale, manufacture, register and commercialize PerFoam 1% for distribution in Israel and the Palestinian territories. The companies did say what the deal was worth. The product is scheduled to be launched in late 2008.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 6 - 13
    Beer Sheva
    13 - 15
    Tel Aviv - Yafo
  • 6 - 7
    Jerusalem
    11 - 12
    Haifa
  • 9 - 17
    Elat
    10 - 15
    Tiberias